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Background: This study investigated whether there were differen-
tial survival outcomes to first-line tyrosine kinase inhibitors (TKI) in 
patients with metastatic non–small-cell lung cancer harboring differ-
ent subtypes of exon 19 and exon 21 mutations on epidermal growth 
factor receptor (EGFR).
Methods: Of 452 patients with stage IIIB and IV non–small-cell 
lung cancer, 192 patients (42.5%) harbored EGFR mutation and 170 
(37.5%) received TKI as first-line treatment. EGFR mutation analy-
sis was performed by direct sequencing. Survival and response out-
come were compared among different subtypes of exon 19 and exon 
21 EGFR mutations in these 170 patients.
Results: Patients harboring exon 19 18-nucleotide deletion 
(delL747_P753insS) had the shortest median progression-free sur-
vival (PFS) (6.5 months), followed by those with 15-nucleotide dele-
tion (delE746_A750) (12.4 months) and mixed insertion/substitution 
mutations (22.3 months; p = 0.012). However, patients who had exon 
19 deletions starting on codon E746 had better median PFS (14.2 
months) than those starting on L747 (6.5 months; hazard ratio, 0.445; 
95% confidence interval [0.219–0.903]; p = 0.021). Besides, exon 
21 L858R derived a longer median PFS than L861R/L861Q (11.4 
months versus 2.1 months, respectively; hazard ratio, 0.298; 95% 
confidence interval [0.090–0.980]; p = 0.034).
Conclusions: Different subtypes of EGFR exon 19 and 21 muta-
tions exhibited differential survival to first-line TKI therapy. Detailed 
sequence evaluation of exon 19 deletions may provide important 
prognostic information on survival outcome after TKI.
Key Words: Non–small-cell lung cancer, Prognostic factors, 
Epidermal growth factor receptor, Tyrosine kinase inhibitors.
(J Thorac Oncol. 2013;8: 1148-1155)
Epidermal growth factor receptor (EGFR) mutations are present in 10% to 50% of patients with stage IV non–
small-cell lung cancer (NSCLC), and are most prevalent 
in adenocarcinoma (AD), East Asians, never-smokers, and 
women.1–3 Mutations resulting in constitutive activation of 
EGFR signaling enhance tumor proliferation, survival metas-
tasis, neovascularization, and other cancer properties. Among 
various types of EGFR mutations, in-frame deletions of exon 
19 (about 44%) encompassing the amino acids from codons 
L747 to E749 (designated as the LRE fragment) and the 
single amino acid mutation L858R in exon 21 (about 41%) 
constitute the most common mutations.4 Other rare mutations 
include G719 resulting in a glycine change to serine, alanine 
or cysteine (about 4%), and other missense mutations (about 
6%). Notably, exon 19 deletion and L858R mutation are gen-
erally considered tyrosine kinase inhibitors (TKI) sensitive 
as the mutant kinases exhibit a reduced affinity for adenos-
ine triphosphate and a relatively higher affinity for binding 
and inhibition by TKI.5 EGFR mutational status is the most 
important determining factor of clinical response to TKI.2,4,5 
Phase II and phase III randomized-controlled trials (RCTs) 
showed superior clinical benefits of TKI in patients with 
EGFR-mutated NSCLC as compared with chemotherapy.6–13 
However, there have been very few studies on the compara-
tive efficacy of TKI for different subtypes of activating EGFR 
mutations, in particular, whether there are survival differ-
ences within exon 19 and exon 21 mutations.14,15 This study 
investigated the differential clinical outcomes of various sub-
types of activating EGFR mutations to first-line TKI therapy.
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PATIENTS AND METHODS
Study Design and Patient Population
All treatment-naive Chinese patients with stage IIIB and 
IV NSCLC diagnosed between January 2006 and June 2011 
were identified. Only those with EGFR mutations and who 
received TKI as their first-line treatment were investigated in 
this study. Baseline workup included hematology and serum 
biochemistry, thoracic and abdominal computed tomography 
(CT), and optional positron-emission tomography integrated 
with CT (PET-CT). All patients with EGFR mutations were 
recommended to receive self-financed gefitinib 250 mg daily 
or erlotinib 150 mg daily according to individual preference 
until disease progression, unacceptable toxicities, or upon self 
withdrawal. Treatment was permanently terminated if inter-
stitial lung disease developed. TKI therapy was suspended 
when toxicities of grade 3 or higher occurred (National 
Cancer Institute Common Terminology Criteria version 3.0) 
and resumed when they returned to grade 1 or baseline.16 
Permanent dose reduction to 5 days a week for gefitinib and 
100 mg daily for erlotinib, respectively, was used when TKI 
was suspended for more than 14 days. Patients were fol-
lowed-up every 4 weeks or more frequently for response and 
adverse events. Tumor response was determined by either CT 
or PET-CT scan (if available at baseline) performed every 12 
weeks or less. The best overall objective response (OR) was 
classified according to Response Evaluation Criteria in Solid 
Tumors version 1.0.17 All ORs were confirmed by repeated 
imaging performed at least 4 weeks after the initial imaging.
EGFR Mutation Evaluation
Before starting TKI therapy formalin-fixed paraffin-
embedded (FFPE) tumor biopsy samples were retrieved for 
EGFR mutation analysis, as previously described.18 Briefly, 
tumor enrichment was performed by microdissection under 
light microscopy. Genomic DNA was extracted using QIAmp 
DNA FFPE Tissue kit (Qiagen, Hilden, Germany), followed 
by polymerase chain reaction (PCR) amplification of EGFR 
exons 18 to 21, using intron-based primers and sequenced in 
both forward and reverse directions.
Statistical Analysis
Differences in progression-free survival (PFS) (the 
time between the date of TKI commencement to the earliest 
sign of disease progression as determined by CT or PET-CT 
imaging, or death from any cause) and overall survival (OS) 
(the time between the commencement of TKI therapy and 
death from any cause) between subgroups were compared by 
log-rank tests. Cox proportional-hazards model was used to 
calculate the hazard ratios [HRs] of the overall population 
and subgroups with age, sex, smoking history, histology (AD 
versus non-AD), Eastern Cooperative Oncology Group per-
formance status (0, 1, 2, 3) and type of TKI as covariates as 
well as for univariate and multivariate analyses. Fisher’s exact 
test or χ2 test was used to compare proportions. A two-sided 
p value less than 0.05 was considered significant. All patients 
were followed-up until death and no patient defaulted on 
follow-up.
RESULTS
Clinical Characteristics
Of 452 patients with stage IIIB and IV disease, 45 
patients had insufficient material for EGFR mutational analy-
ses. There were 192 patients (42.5%) with EGFR mutations, 
170 of whom (37.6%) received first-line TKI therapy, including 
139 who received gefitinib and 31 who received erlotinib. The 
clinicopathological data were summarized (Table 1). As shown, 
the most common mutation was L858R mutation (47.1%) fol-
lowed by exon 19 in-frame deletions (37.6%). For the 64 tumors 
with exon 19 deletions, we classified them into three subtypes 
according to the number of deleted nucleotides, comprising 42 
tumors (24.7%) with 15-nucleotide deletion (delE746_A750, 
named as 15n-del), 10 (5.9%) with 18-nucleotide deletion 
(delL747_P753insS, named as 18n-del), and 12 (7.1%) with 
various exon 19 deletions that incorporated other insertion/
substitutions (named as mixed ins/sub; Tables 2 and 3). Gazdar 
et al.4 subcategorized EGFR mutant tumors according to the 
starting codon of exon 19 deletions. Using this classifica-
tion, 46 tumors (27.1%) had deletions starting at E746 (E746 
group), 16 (9.4%) at L747 (L747 group), and two (1.2%) at 
T751 (non-LRE group). For exon 20 mutations, there were five 
tumors harboring in-frame, nine-nucleotide tandem duplica-
tions (1 at A767_V769, 1 at N771_H773, and 3 at S768_D770), 
one tumor harboring a three-nucleotide tandem duplication 
(H773_V774InsH) and another tumor having K757R mutation. 
In addition, 11 tumors (6.5%) had double mutations, of which 
the known activating mutations L858R and L861Q were most 
commonly present, involving six and two tumors, respectively, 
as shown in Table S1 (Supplemental Digital Content 1, http://
links.lww.com/JTO/A458). We also observed the previously 
known TKI-resistant T790M mutation in three patients but they 
were not included in this study because all of them received 
TKI as second-line treatment after progression to first-line che-
motherapy.19–21 Four rare mutations (exon 18 G724S, exon 18 
delE709_T710insD, exon 20 K757R, and exon 21 R831H) in 
four distinct patients were also identified.22
Survival Analysis and Prognostic Factors
At the time of statistical analysis (May 31, 2012), the 
cohort had a median follow-up of 46.2 months (range, 0.72–
72.1 months), 58 patients were progression-free and 89 were 
still alive. The median PFS was 12.4 months whereas the 
median OS has not yet been reached. The best responder in 
our study has been on TKI for 63.0 months and remains pro-
gression-free. No patient has permanently stopped TKI ther-
apy. Although there was an imbalance of number of patients 
receiving the two TKIs because of personal choice, no differ-
ences were observed in PFS (11.4 months for gefitinib and 
11.2 months for erlotinib; HR, 1.131; 95% confidence inter-
val [CI] [0.674–1.897]; p = 0.641) and OS (23.2 months for 
gefitinib and not reached for erlotinib; HR, 1.026; 95% CI 
[0.540–1.949]; p = 0.937).
Progression-Free Survival
The median PFS was significantly different for mutations 
on different exons (p < 0.0001; Fig. 1A). Patients with exon 20 
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mutation had the shortest median PFS (2.1 months), followed 
by those with double mutations (4.2 months), exon 21 muta-
tion (10.6 months), and exon 19 deletions (12.8 months). Exon 
18 had the longest PFS (13.9 months) but only three belonged 
to this group. In subgroup analyses, patients with exon 19 dele-
tions enjoyed significantly longer median PFS (12.8 months) 
than those with L858R mutation (11.4 months; HR, 0.649; 
95% CI [0.416–0.983]; p = 0.040; Fig. 1B). Significant dif-
ferences in PFS were also noted among the three subtypes of 
exon 19 deletions. The 18n-del group had the shortest median 
PFS (6.5 months) followed by a significantly longer median 
PFS in the 15n-del group (12.4 months) and the mixed ins/sub 
group (22.3 months; p = 0.021; Fig. 1C). Using Gadzar’s clas-
sification of exon 19 deletion patterns, we observed the E746 
TABLE 1.  Baseline Characteristics of the Study Population
Characteristic
No. of Patients (%) 
(n = 170)
Gefitinib Group (%) 
(n = 139)
Erlotinib Group (%) 
(n = 31) p
Sex
  Male 56 (32.9) 36 (25.9) 20 (64.5) 0.000
  Female 114 (67.1) 103 (74.1) 11 (35.5)
Age 28–86 36–86 28–85
  Mean 64.5 64.8 61.7 0.214
  Median 65.5 66.0 60.0 0.220
Smoking status
  Never smoker 136 (80.0) 116 (83.5) 20 (64.5) 0.023
  Chronic smoker 11 (6.5) 6 (4.3) 5 (16.1)
  Ex-smoker 23 (13.5) 17 (12.2) 6 (19.4)
ECOG performance
  0 1 (0.6) 1 (0.7) 0 (0.0) 0.036
  1 149 (87.6) 125 (89.9) 24 (77.4)
  2 16 (9.4) 9 (6.5) 7 (22.6)
  3 4 (2.4) 4 (2.9) 0 (0.0)
Histology
  Adenocarcinoma 154 (90.1) 128 (92.1) 26 (83.8) 0.045
  Squamous cell carcinoma 2 (1.1) 0 (0.0) 2 (6.5)
  Adenosquamous carcinoma 4 (2.4) 4 (2.9) 0 (0.0)
  NSCLC, not other specified 10 (5.9) 7 (5.0) 3 (9.7)
Clinical stage
  IIIB 25 (14.7) 20 (14.4) 5 (16.1) 0.805
  IV 145 (85.3) 119 (85.6) 26 (83.9)
Brain metastasis 39 (22.9) 30 (21.6) 9 (29.0) 0.372
Type of EGFR mutations
  Exon 18 mutation 3 (1.8) 1 (0.7) 2 (6.5) 0.028
  Exon 19 deletion 64 (37.6) 52 (37.4) 12 (38.7) 0.893
   Number of nucleotide deletion
    15-nucleotide deletion (15n-del) 42 (24.7) 34 (24.5) 8 (25.8) 0.977
    18-nucleotide deletion (18n-del) 10 (5.9) 8 (5.8) 2 (6.5)
    Other insertion/substitution (mixed ins/sub) 12 (7.1) 10 (7.2) 2 (6.5)
   Deletion starting codon
    E746 group 46 (27.1) 38 (27.3) 8 (25.8) 0.512
    L747 group 16 (9.4) 13 (9.4) 3 (9.7)
    Non-LRE group 2 (1.2) 1 (0.7) 1 (3.2)
  Exon 20 mutation 7 (4.1) 6 (4.3) 1 (3.2) 0.782
  Exon 21 mutation 85 (50.0) 72 (51.8) 13 (41.9) 0.321
   L858R 80 (47.1) 68 (48.9) 12 (38.7) 0.303
   L861Q 3 (1.7) 2 (1.4) 1 (3.2) 0.494
   L861R 1 (0.6) 1 (0.7) 0 (0.0) —
   R831H 1 (0.6) 1 (0.7) 0 (0.0) —
  Double mutations 11 (6.5) 8 (5.8) 3 (9.7) 0.422
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer.
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group had a longer median PFS (14.2 months) compared with 
L747 group (6.5 months; HR, 0.445; 95% CI [0.219–0.903]; p 
= 0.021; Fig. 1D). For the two patients belonging to non-LRE 
group, one had a PFS of 13.3 months and the other patient 
was still free from progression after taking TKI for 2.4 months. 
They were not included in statistical analysis because of the 
small number of patients. Comparing L858R versus L861Q/
L861R mutation, we found that PFS was significantly longer 
with L858R (11.4 months versus 2.1 months, respectively; 
HR, 0.298; 95% CI [0.090–0.980]; p = 0.034), regardless of 
whether L858R or L861Q occurred alone or as part of a double 
mutation (Fig. 1E). Both univariate and multivariate analyses 
revealed that mixed ins/sub group (p = 0.021 and p = 0.011, 
respectively) and E746 group (p = 0.021 and p = 0.033, respec-
tively) were the only two prognostic factors of PFS.
Overall Survival
The median OS was not reached in the study population. 
There was no difference in OS among mutations on different 
exons (p = 0.327; Fig. 2A) or between exon 19 deletions (24.6 
months) and L858R mutation (21.0 months; HR, 0.732; 95% 
CI [0.446–1.201]; p = 0.209; Fig. 2B). No significant differ-
ence in OS was observed among each subtype of exon 19 
deletions (23.8 months for 15n-del, 17.7 months for 18n-del, 
and not reached for mixed ins/sub group; p = 0.240; Fig. 2C), 
or between E746 group (24.6 months) and L747 group (17.7 
months; HR, 1.547; 95% CI [0.666–3.596]; p = 0.307) accord-
ing to Gadzar’s classification (Fig. 2D). Notably, patients with 
L858R had significantly better OS (21.0 months) than those 
with L861Q/L861R mutation (8.7 months, HR, 0.236; 95% 
CI [0.069–0.805]; p = 0.012; Fig. 2E). Univariate and mul-
tivariate analyses did not reveal any prognostic factor of OS.
Objective Response
The overall OR was 75.3% for the whole population, 
and eight patients (4.7%) had complete remission. ORs for 
exon 18, exon 19, exon 20, exon 21, and double mutations 
were 33.3%, 87.5%, 14.3%, 75.3%, and 54.5%, respectively. 
TABLE 2.  Characteristics of Patients Harboring Exon 19 18-Nucleotide Deletion (delL747_P753insS)
Age Sex Smoking Status Histology Nucleotide Amino Acid Response Duration of TKI (mo) Progression
34 M Chronic smoker NSCLC NOS del2240-2257 delL747_P753insS PR 2.1 Yes
71 M Never AD del2240-2257 delL747_P753insS PR 3.2 Yes
77 F Never AD del2240-2257 delL747_P753insS PR 3.9 No
74 F Never AD del2240-2257 delL747_P753insS PR 5.3 Yes
54 F Never AD del2240-2257 delL747_P753insS PR 5.8 Yes
47 F Never AD del2240-2257 delL747_P753insS PR 6.5 Yes
61 M Never AD del2240-2257 delL747_P753insS PR 8.3 Yes
71 F Never AD del2240-2257 delL747_P753insS PR 12.2 Yes
75 M Chronic smoker AD del2240-2257 delL747_P753insS PR 12.7 No
56 M Never AD del2240-2257 delL747_P753insS SD 15.3 Yes
TKI, tyrosine kinase inhibitor; NSCLC NOS, non–small-cell lung cancer not otherwise specified; AD, adenocarcinoma; PR, partial response; SD, stable disease.
TABLE 3.  Characteristics of Patients Harboring Exon 19 Deletion with Other Insertion/Substitution
Age Sex
Smoking  
Status Histology Nucleotide Amino Acid Response
Duration of TKI 
Therapy (mo) Progression
36 M Never NSCLC NOS del2239-2262 replaced by  
GCCAACAAGGGA
delL747_ 
K754insANKG
PD 0.7 Yes
58 F Never AD del2239-2248 replaced by C delL747_A750insP PD 1.5 Yes
71 F Never NSCLC NOS del2250-2277 replaced by CAAC delT751_I759insN PR 2.4 No
45 F Never AD del2239-2248 replaced by C delL747_A750insP PR 5.7 Yes
73 F Never AD del2237-2253 replaced by TC delE746_T751insV CR 7.6 No
58 M Never AD del2252-2776 replaced by G delT751_I759insS PR 13.3 Yes
51 F Never AD del2235-2252 replaced by AAT delE746_T751insI PR 16.1 No
46 M Never AD del2240-2264 replaced by  
CGAAAGG
delL747_A755insSKG PR 18.3 Yes
56 F Never AD del2237-2253 replaced by  
TTGCT
delE746_T751insVA CR 22.3 Yes
79 M Ex-smoker AD del2239-2251 replaced by C delL747_T751insP CR 40.6 No
64 F Ex-smoker AD del2237-2255 replaced by T delE746_S752insV PR 43.1 No
76 M Never AD del2237-2248 replaced by CAC delE746_A750insAP PR 63.0 No
NSCLC NOS, non–small-cell lung cancer not otherwise specified; AD, adenocarcinoma; CR, complete response; PR, partial response; SD, stable disease, PD, progressive disease.
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OR was slightly higher for exon 19 deletions than L858R 
(87.5% versus 75.3%, respectively), reaching borderline sig-
nificance (p = 0.065). ORs among each subtype of exon 19 
deletions were similar, namely 88.1%, 90.0%, and 83.3% 
for 15n-del, 18n-del, and mixed ins/sub group, respectively 
(p = 0.878). Similarly, OR of E746 group (89.1%) was not dif-
ferent from those of L747 group (81.3%; p = 0.418). Partial 
response was noted in the two patients in non-LRE group. OR 
between L858R and L861Q/L861R were not different from 
each other (76.3% versus 75.0%, respectively; p = 0.954).
Salvage Therapy after Progression 
to First-Line TKI
For the 112 patients who developed progression after 
first-lineTKI, 39 patients (34.8%) received chemotherapy 
after progression to TKI and they received on average 1.46 
lines of chemotherapy. Another 35 patients (31.3%) received 
second-line TKI after progression to the first-line TKI. Of 
these, 33 patients (94.3%) received the second-line TKI as 
their only additional line of TKI. One patient (2.9%) received 
the second-line TKI and then the first TKI again as the sec-
ond- and third-line treatment. Another patient (2.9%) received 
these two TKIs again as the second-, third-, and fouth-line 
treatment. Use of chemotherapy and TKI after progression to 
first-line TKI therapy were not prognostic factors of OS.
DISCUSSION
Before the advent of TKI, the overall prognosis of NSCLC 
remained poor.23 The discovery of EGFR tyrosine kinase 
domain mutations that predict responsiveness to TKI results in 
promising repercussion for both physicians and patients. Many 
international multicenter RCTs7–13 have demonstrated that TKI 
is superior to chemotherapy as a first-line therapy for meta-
static NSCLCs harboring certain activating EGFR mutations 
but further details on the response pattern are limited. This 
study reviewed a homogeneous population of Chinese patients 
FIGURE 1.  PFS for EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. A, PFS for patients with different 
types of EGFR mutations. B, PFS for patients with either exon 19 deletion or L858R mutation. C, PFS for patients with different 
subtypes of exon 19 deletions. D, PFS for patients with subtypes of exon 19 deletions according to Gadzar’s classification. E, 
PFS for patients with either L858R or L861Q/L861R mutation. EGFR, epidermal growth factor receptor; PFS, progression-free 
survival.
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treated with first-line TKI in a single institution. Our study 
population was double of that randomized to the TKI arm in 
RCTs comparing first-line TKI against chemotherapy includ-
ing North-East Japan Study Group, WJTOG3405, OPTIMAL, 
EURTAC, and was seven times the study population of First-
SIGNAL with confirmed EGFR mutation and randomized to 
TKI treatment.8–11,13 In the Iressa Pan-Asia Study, only 132 
patients with confirmed EGFR mutation received TKI, less 
than the 170 patients in our study.7 Our results showed that 
although patients with exon 19 deletions and L858R had simi-
lar response rates, those with exon 19 deletions had a longer 
median PFS than L858R mutations. This observation con-
curred with the results from subgroup analyses of previously 
published single-arm studies.8–10 Nevertheless, this has not 
been addressed or demonstrated in phase III RCTs, including 
North-East Japan Study Group, WJTOG3405, Iressa Pan-Asia 
Study, European Tarceva versus Chemotherapy (EURTAC) 
study, OPTIMAL, and First-SIGNAL.7–13
Exon 19 deletions contain a large number of variants 
involving in-frame deletions or mixed insertion/substitutions. 
By categorizing exon 19 deletions into subtypes including 15n-
del, 18n-del, and mixed ins/sub groups, we found that 18n-del 
had the shortest median PFS (6.5 months), followed by those 
with 15n-del (12.4 months) and mixed ins/sub (22.3 months). 
This finding of differential survival outcomes to TKI in patients 
with different subtypes of exon 19 deletions has not been pre-
viously reported. In our study, there was a rather wide range of 
PFS in patients in 18n-del group (2.1–15.3 months) and mixed 
ins/sub group (0.7–63.0 months). The few patients who had 
very short PFS could harbor tumor cell subclones with preex-
isting or rapidly acquired TKI-resistant mutations before start-
ing TKI therapy. However, we did not perform rebiopsy after 
FIGURE 2.  OS for EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. A, OS for patients different types of 
EGFR mutations. B, OS for patients with either exon 19 deletion or L858R mutation. C, OS for patients with different subtypes of 
exon 19 deletions. D, OS for patients with subtypes of exon 19 deletions according to Gadzar’s classification. E, OS for patients 
with either L858R or L861Q/L861R mutation. EGFR, epidermal growth factor receptor; OS, overall survival.
1154 Copyright © 2013 by the International Association for the Study of Lung Cancer
Lee et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 9, September 2013
progression to TKI to further delineate the genetic cause of TKI 
resistance because this was not our study objective. Gadzar et 
al. showed that the most common and shortest recurrent dele-
tion in exon 19 encompassed the LRE amino acids encoded 
by codons L747 to E749.4 According to Catalogue of Somatic 
Mutations in Cancer Database,24 the most commonly involved 
deletion around the LRE fragment is delE746_A750 (66.1%), 
followed by delL747_P753insS (56.8%), delL747_A750insP 
(4.0%), and delL747_T751 (3.7%), whereas the most com-
mon non-LRE deletion is delS752_I759. Most recently, Chung 
et al.14 reported that LRE deletions derived better OR but no 
significant difference in PFS or OS to TKI compared with 
non-LRE deletions. Under this categorization, we have demon-
strated superior PFS in E746 group compared with L747 group 
though no difference in OR was observed between these two 
groups. However, our result could not be directly compared 
with those of Chung et al. In their study, a heterogeneous popu-
lation was analyzed including those using TKI as second- and 
third-line treatment, and only 114 of 308 (37.0%) received 
TKI as first-line therapy. In the non-LRE group of the study 
by Chung et al., seven patients received TKI and only three 
received it as first-line therapy. As suggested by the explor-
atory evidence of Iressa NSCLC Trial Evaluating REsponse 
and Survival versus Taxotere (INTEREST) study, prior first-
line chemotherapy might have caused a bias in the tumor cell 
composition and reduced efficacy of second-line TKI, leading 
to an inferior outcome of non-LRE group in Chung’s study.14,25 
However, Taron et al.15 reported that the number of amino acids 
deleted in exon 19 did not correlate with treatment outcomes 
to erlotinib. However, the data were published in an abstract 
only and further elaboration such as the pattern of exon 19 
deletion and the setting of erlotinib treatment was not avail-
able. From our study, it seemed that those who simultaneously 
belonged to E746 and mixed ins/sub groups derived the lon-
gest PFS (Table 4). In addition, we found that patients with 
L861Q mutation had a shorter response duration and survival 
compared with L858R, providing clinical evidence to the find-
ings in a previous cell line study.26
Various EGFR mutation analysis methods such as the 
Amplification Refractory Mutation System, DxS EGFR29 
mutation-detection kit, protein nucleic acid-locked nucleic 
acid PCR clamp method, and Cycleave method have been 
adopted in combination or as the sole test in different inter-
national RCTs.8–11,27–29 PCR-based methods designed to detect 
specific mutations, especially substitution mutations, enjoy 
the advantages of high sensitivity and applicability in small 
samples and short turnaround time. These quick kits require 
only a very minute amount of allelic concentration (1%) with 
detection limits of 5 to 10 copies.27,28 Although these kits may 
have higher sensitivity for some types of EGFR mutations, 
only common mutations are covered and the results do not 
provide detailed sequence data, particularly the exact num-
ber of deleted nucleotides and the starting codon of exon 19 
deletions.30 It is uncertain whether rare exon 19 insertions or 
substitutions could all be detected by these kits, undermin-
ing the interpretation of important prognostic information. For 
cases with adequate DNA for analysis, direct sequencing still 
has a crucial role in identifying rare but clinically meaningful 
EGFR mutations.30 More advanced techniques such as mass 
spectrometry genotyping assay and next-generation sequenc-
ing might be able to provide more quantitative measures of the 
profile and prevalence of different mutations.19,31,32
There are several limitations in our study. First, this is a 
retrospective study that may contain selection bias. Also there 
were more patients who received gefitinib than those who had 
erlotinib as first-line TKI. However, this confounding factor 
was adjusted during analysis of survival difference between 
subgroups. In addition, there was no clear biological expla-
nation for the difference of survival outcomes for different 
subgroups of exon 19 deletions. Perhaps crystal structural 
analyses of different subgroups may provide insights on the 
effect of EGFR activation and TKI response.
In conclusion, different subtypes of EGFR mutations 
especially exon 19 deletions demonstrated differential PFS out-
comes after first-line TKI therapy. This finding cautions that not 
all exon 19 deletions have equally favorable response to TKI and 
clinicians should adopt more dedicated surveillance after TKI 
commencement to detect early progression in patients whose 
tumors harbor unfavorable deletion patterns in their tumors.
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